Article thumbnail

Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis

By Dennis A Revicki, Anne M Rentz, Michelle P Luo and Robert L Wong
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1994). A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.
  2. (1998). A: Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol
  3. (1996). A: The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).
  4. (2009). Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis
  5. (2007). Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol
  6. (2001). Ankylosing spondylitis assessment group preliminary definition of shortterm improvement in ankylosing spondylitis. Arthritis Rheum
  7. Ankylosing spondylitis: history. In Rheumatology. Edited by: Klippel JK,
  8. (1984). Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum
  9. (1951). Coefficient alpha and the internal structure of tests. Psychometrika
  10. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.
  11. (2003). Der Linden S: Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis
  12. (2003). Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis
  13. (2000). Disability and handicap in rheumatoid arthritis and ankylosing spondylitis–results from the German rheumatological database. German Collaborative Arthritis Centers.
  14. (2004). DM: Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum
  15. (2006). Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum
  16. (2005). Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum
  17. (2000). EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis
  18. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer
  19. (1994). Functional assessment in ankylosing spondylitis: evaluation of a new self-administered questionnaire and correlation with anthropometric variables.
  20. (2003). Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int
  21. (1993). Gandek B: SF-36 Health Survey: Manual and Interpretation Guide.
  22. IH: Psychometric Theory.
  23. (2007). Improvement in patientreported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford)
  24. (2007). Luo MP: Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum
  25. (2007). Maksymowych WP: Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, doubleblind, placebo-controlled study. Arthritis Rheum
  26. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage
  27. (2007). MP: Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. Health Qual Life Outcomes
  28. (2002). PT: Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology
  29. (2003). PT: Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index.
  30. (2005). PT: Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford)
  31. (1998). Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am
  32. (2003). Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum
  33. (2000). Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res
  34. (1994). S: SF-36 Physical and Mental Health Summary Scores: A User’s Manual.
  35. (2005). Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis
  36. (1994). T: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.
  37. (2004). TK: Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis
  38. (2002). Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet
  39. (2002). Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
  40. (2005). Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis
  41. (2005). Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.
  42. (2002). van der Heijde D: Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum
  43. (2001). Zink A: Ankylosing spondylitis: an overview. Ann Rheum Dis